Objective-Akkermansia muciniphila (A muciniphila) is a mucin-degrading bacterium that resides in the mucus layer whose abundance inversely correlates with body weight and the development of diabetes mellitus in mice and humans. The objective of this study was to explore the regulatory effect of A muciniphila on host lipoprotein metabolism, insulin sensitivity, and hepatic metabolic inflammation. Approach and Results-By establishing a novel mouse model that colonized the A muciniphila in the gastrointestinal tract of the cAMP-responsive binding protein H (CREBH)-deficient mouse and in vivo chylomicron assay, we found that increased colonization of A muciniphila in the gastrointestinal tract of wild-type mice protected mice from an acute fat load-induced hyperlipidemia compared with vehicle-treated mice. A muciniphila administration also significantly ameliorated chronic hypertriglyceridemia, improved insulin sensitivity, and prevented overproduction of postprandial chylomicrons in CREBH-null mice. Mechanistic studies revealed that increased A muciniphila colonization induced expression of low-density lipoprotein receptors and apolipoprotein E in the hepatocytes of CREBH-null mice, which facilitated the uptake of intermediate-density lipoprotein via the mediation of apolipoprotein B100 and apolipoprotein E, leading to the increased clearance of triglyceride-rich lipoprotein remnants, chylomicron remnants, and intermediatedensity lipoproteins, from the circulation. Treatment with A muciniphila further improved hepatic endoplasmic reticulum stress and metabolic inflammation in CREBH-null mice. Conclusions-Increased colonization of the disease-protective gut bacteria A muciniphila protected the host from acute and chronic hyperlipidemia by enhancing the low-density lipoprotein receptor expression and alleviating hepatic endoplasmic reticulum stress and the inflammatory response in CREBH-null mice.
T he human gastrointestinal tract is populated with at least 100 trillion bacteria that provide their host with dietary metabolites. Extensive studies have demonstrated that human gut microbiota affect energy balance, gut permeability, serum lipopolysaccharides levels, and metabolic inflammation associated with obesity and diabetes mellitus. 1 Subjects with obesity and type 2 diabetes mellitus are characterized by altered gut microbiota, inflammation, and gut barrier disruption. In addition, the population of beneficial gut bacteria has been found to be reduced in animal models of metabolic syndrome. For instance, the abundance of a beneficial gut bacterium, Akkermansia muciniphila (A muciniphila), is significantly lower in the genetically obese ob/ob mice or mice fed a high-fat diet compared with their lean littermates. Increased colonization of A muciniphila has also been found to be capable of reversing high-fat diet-induced metabolic disorders. 2 In contrast, disease-promoting gut bacteria induce metabolic disorders. For instance, a strain of the Enterobacter cloacae, B29, isolated from a morbidly obese human, induced obesity and insulin resistance in a rodent model, and the severity of disease was found to be closely related to the lipid content in the diet. 3 A muciniphila is a mucin-degrading bacterium that resides in the mucus layer of intestine, and it abundantly colonizes in this nutrient-rich environment. 4 Oral administration of live A muciniphila has been shown to prevent diet-induced obesity by altering adipose tissue metabolism and gut permeability without affecting food intake. 2 However, the regulatory effect of A muciniphila on host lipid metabolism, particularly on hepatic lipid signaling and lipoprotein metabolism, is unexplored.
The intestinal epithelium is the interface for the interaction between gut microbiota and host tissues. 5 This barrier is enhanced by the presence of a mucus layer and immune factors that are produced by the host. 6 Increased gut permeability, which results in increased lipopolysaccharides absorption, has been identified to be associated with the metabolic inflammation developed in metabolic syndrome. 7, 8 Chylomicrons, the lipoproteins that transport the long chain and very long chain fatty acids in our diet from the intestine to peripheral tissues and organs, have been reported to promote the absorption of purified exogenous lipopolysaccharides delivered through oral gavage. 9 Sequestration of absorbed lipopolysaccharides on chylomicrons would reduce lipopolysaccharides toxicity and enhance its hepatic clearance. 9 In contrast, excess chylomicron formation during high-fat feeding, which leads to prolonged chylomicronemia, could augment extrahepatic lipopolysaccharides exposure and increase the risk for atherosclerosis and other metabolic or inflammatory disorders. This evidence indicates that lipid and lipoproteins are potentially critical links between the gut microbiota and the host metabolic system.
The cAMP-responsive element-binding protein H (CREBH) is an endoplasmic reticulum (ER)-bound transcription factor that belongs to the same b-zip family as sterol regulatory element-binding proteins. 10 CREBH is selectively and highly expressed in the liver and the small intestine, and it has been shown to enhance hepatic gluconeogenesis, increase hepatic fatty acid β-oxidation, and regulate lipoprotein lipase (LPL) activity. 11, 12 Genetic depletion of CREBH in mice induced hypertriglyceridemia with the triglyceride content specifically increased in very low-density lipoprotein (VLDL) particles. 13 In humans, heterozygous nonsynonymous or insertional mutations in CREBH (CREB3L3) have been found to cause severe hypertriglyceridemia. 13 The unique tissue distribution of CREBH (eg, only expressed in the gut and liver) and its role in lipid metabolism makes CREBH-null mice a suitable animal model for study of the mutualism between the gut microbiota and the host lipid metabolism. Therefore, the goal of this study was to investigate the impact of A muciniphila on intestinal chylomicrons and hepatic VLDL metabolism and to ascertain the mechanism of its antihypertriglyceridemic effect using CREBH-null mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Increased Colonization of A muciniphila Protects the Host From Acute Lipid Overload-Induced Hyperlipidemia
To investigate the impact of A muciniphila on acute intestinal lipid absorption and chylomicron metabolism, 2 groups of 12-week-old C57BL/6J mice were inoculated with 200 μL of A muciniphila (2×10 8 cfu/0.2 mL) in PBS, or the vehicle (PBS) alone as control, every other day through oral gavage for 2 weeks. Body weight and plasma lipid content were monitored weekly, and food intake was monitored twice a week during the trial. Body weight and food intake were found to be maintained at comparable levels between A muciniphila-treated and control mice, which were consistent with the previous report 2 ( Figure IA in the online-only Data Supplement and data not shown). Compared with the baseline plasma lipid content before A muciniphila treatment, no significant changes were observed in the plasma triglyceride and cholesterol contents at 1 or 2 weeks post A muciniphila treatment ( Figure IB in the online-only Data Supplement). At the end of week 2, mice were administrated with a dose of olive oil (200 μL) orally after 12 hours of fasting. Mice were further treated with poloxamer (500 mg/kg) at 20 minutes after the fat load through intraperitoneal injection to inhibit the activity of LPL and prevent hydrolysis of lipoproteins in the circulation. Blood samples were collected at 1 and 2 hours after poloxamer injection. On analysis of the abundance of A muciniphila and other major gut bacterial strains in the cecal contents, populations of A muciniphila, Firmicutes, Bacteroides-Prevotella, Bacteroidetes, and Lactobacillus were found to be significantly higher in the A muciniphilatreated mice compared with the control group ( Figure IC in the online-only Data Supplement), indicating that the inoculated A muciniphila were successfully colonized in the mouse cecum and modified the gut bacterial community structure. Plasma triglyceride and cholesterol levels were found to be similar between the groups at baseline (0 hours) without lipid stimulation ( Figure 1A ). However, challenge of the mice with an acute fat load elevated plasma triglyceride in both the vehicle-treated group and the A muciniphila-treated group at 1 hour compared with 0 hours. Plasma triglycerides were further increased in both the groups at 2 hours post fat load and the triglycerides, at this point, were significant lower in the A muciniphila group compared with the vehicle group ( Figure 1A ). In parallel with the plasma lipid content, protein expression of apolipoprotein B48 (apoB48) and apoB100, the key structural proteins in chylomicrons and VLDL, were comparable between the 2 groups at time 0 ( Figure 1B ), but were significantly induced in the vehicle group compared with the A muciniphila-treated group at 2 hours post fat gavage ( Figure 1C ), indicating increased secretion or decreased clearance of chylomicrons and VLDL in the vehicle-treated group. On further examination of the liver and small intestinal tissues, apoB100 and apoB48 were found to be significantly increased in the control group compared with the A muciniphila group ( Figure ID in the onlineonly Data Supplement and Figure 1D ). These results suggest that increased colonization of A muciniphila in the intestine protects mice from acute lipid load-induced overproduction of chylomicrons and VLDL, therefore, contributes to the maintenance of lipid metabolic homeostasis in the host.
Akkermansia muciniphila Ameliorates Chronic Hyperlipidemia Induced by Depletion of CREBH
To investigate whether increased colonization of A muciniphila is capable of ameliorating chronic hyperlipidemia induced by genetic intervention, we used the wild-type (WT) and CREBH-null (KO) mice, which are genetically hypertriglyceridemic because of CREBH depletion. Depletion of CREBH did not significantly alter the abundance of A muciniphila in the gastrointestinal tract of CREBH-null mice compared with the WT mice ( Figure IIA in the online-only Data Supplement). Next, 2 groups of the CREBH-null mice and their WT littermates were subjected to oral gavage with 200 μL of either vehicle or A muciniphila every other day for 2 weeks. No significant differences were observed on body weight or food intake between the A muciniphila groups and the control groups during the trial ( Figure IIB in the online-only Data Supplement and data not shown). At the end of week 2, the 2 groups of CREBH-null mice were subjected to an oral glucose tolerance test. On analysis of the blood glucose levels at 0, 30, 60, and 90 minutes post glucose delivery, A muciniphila inoculation was found to improve glucose intolerance in the CREBH-null mice ( Figure 2A ). Determination of the plasma lipid content further showed that A muciniphila did not induce significant changes in plasma triglyceride or cholesterol in the WT mice ( Figure 2B ). However, in the CREBH-null mice, plasma triglyceride was significantly lower in the A muciniphila group compared with the vehicle group ( Figure 2B) . A slight reduction of cholesterol was also noticed in the treated mice compared with the controls, although not statistically significant ( Figure 2B ). To further investigate whether A muciniphila has to be alive to exert its metabolic regulatory effects, viable A muciniphila and heatinactivated A muciniphila were administrated into 2 groups of the CREBH-null mice for 2 weeks. We found that inactive A muciniphila was unable to improve glucose intolerance and hyperlipidemia in CREBH-null mice ( Figure 2C and Figure  IIC in the online-only Data Supplement). Determination of the plasma apoB protein levels by immunoblotting analysis showed that A muciniphila treatment significantly reduced plasma apoB100 in the CREBH-null mice but had no significant impact on the WT mice ( Figure 2D ). These intriguing data further suggest that A muciniphila may exert its regulatory effect only in mice with abnormal lipid contents, which may have significant clinical implications. In addition, the effect of A muciniphila on apoB in CREBH-null mice further suggests a reduced hepatic VLDL assembly and secretion or increased clearance of intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) from the circulation.
LDL Receptor Mediates the Triglyceride-Lowering Action of Akkermansia muciniphila
To investigate the mechanism for the dramatically reduced plasma triglyceride contents and apoB100 levels in the A muciniphila-treated CREBH-null mice, we first focused on the molecules that are involved in the lipoprotein clearance pathway. Previously, defective expression of the LPL coactivators apoC2, apoA4, and apoA5, which causes inefficient hydrolysis of lipoprotein triglycerides by LPL, has been proposed to be partially responsible for the hypertriglyceridemia observed in the CREBH-null mice. 13 We thus tested whether A muciniphila treatment was capable of restoring the mRNA expression levels of these LPL cofactors by quantitative real-time RT-PCR. However, we did not observe significant differences in the expression of, apoA4, apoA5, or apoC2 mRNA in the A muciniphila-treated or vehicle-treated mice (Figure IIIA-IIIC in the online-only Data Supplement), suggesting that enhanced lipoprotein hydrolysis is not a major mechanism for the triglyceride-lowering action of A muciniphila in CREBH-null mice. Further investigation of the LDL receptor pathway revealed that protein expression of the LDL receptor was significantly upregulated in the livers of A muciniphila-treated CREBH-null mice compared with the vehicle or inactive A muciniphila-treated mice ( Figure 3A and Figure IVA in the online-only Data Supplement). Analysis of the plasma lipoprotein profile by gel filtration fast-phase liquid chromatography showed that A muciniphila treatment significantly decreased triglyceride contents in the VLDL particles ( Figure 3B ). More important, inoculation of A muciniphila also reduced triglycerides in the VLDL remnants and IDL and LDL in CREBH-null mice ( Figure 3B ), indicating an increased clearance of IDL and LDL from the circulation. A small decrease in cholesterol was also noticed in the VLDL, IDL, LDL, and larger high-density lipoprotein (HDL) particles, which may also resulted from increased clearance of VLDL remnants by the upregulated LDL receptor signaling on A muciniphila treatment ( Figure 3C ). Consistent with increased expression of the LDL receptors and the subsequent facilitation of IDL and LDL uptake by the liver, hepatic apoB100 were significantly higher in the KO/A muciniphila group compared with the KO/vehicle group ( Figure 3D ). Protein mass of apoE, a component of VLDL particles, was also upregulated in the KO/A muciniphila group compared with the KO/ vehicle groups ( Figure 3D) . A muciniphila treatment did not significantly alter the expression of apoB48 in the small intestine under basic physiological condition ( Figure IVB in the online-only Data Supplement). To further determine the specificity of LDL receptor pathway in mediating this event, we treated 2 groups of LDL receptor knockout mice with A muciniphila or vehicle in the same protocol and found that inoculation of A muciniphila failed to improve insulin sensitivity and hypercholesterolemia in the LDL receptornull mice in the 2-week treatment time course (Figures IVC and IVD in the online-only Data Supplement), suggesting that LDL receptor signaling is essential in mediating the triglyceride-lowering action of A muciniphila in mice. Together, these results indicate that increased colonization of A muciniphila in the gastrointestinal tract of CREBH-null mice upregulates LDL receptor expression, which would in turn facilitate the uptake of VLDL remnants by the liver through the mediation of apoB100 and apoE on IDLs and apoB100 on LDLs. This would result in the increased clearance of triglycerides from blood circulation.
Akkermansia muciniphila Treatment Facilitates Clearance of Plasma Chylomicrons in CREBH-Null Mice
To test whether increase colonization of A muciniphila inhibits intestinal chylomicron assembly and secretion, we treated 2 groups of CREBH-null mice with A muciniphila or vehicle. At the end of week 2, mice were subjected to an in vivo chylomicron collection assay as detailed in Materials and Methods section of this article. On analysis of the plasma apoB protein content by immunoblotting, the basal levels of apoB100 in plasma were found to be significantly lower in the KO/A muciniphila-treated mice compared with controls, whereas apoB48 were comparable between these 2 groups ( Figure 4A ). Gavage with olive oil (200 μL) followed by poloxamer treatment greatly induced accumulation of apoB48, a major component of chylomicrons, in the plasma of KO/vehicle mice, which reached statistical significance at 2 hours post treatment ( Figure 4B ). In contrast, no significant difference was observed in plasma apoB100 level between the A muciniphila-treated and the control group after fat gavage. We further investigated whether the inactive A muciniphila has similar regulatory effects on chylomicron metabolism as the viable one by inoculating 2 groups of CREBH-null mice with either alive or heat-inactivated A muciniphila followed by a chylomicron collection assay. As shown in Figure V in the onlineonly Data Supplement, inactive A muciniphila failed to reduce plasma apoB protein levels at baseline (time 0) or after a fat load ( Figure VA and VB in the online-only Data Supplement).
To determine whether the reduced plasma chylomicrons were caused by impairment of intestinal fat absorption and the subsequent inhibition of chylomicron biosynthesis in the A muciniphila-treated mice, we measured the lipid contents in the jejunum of KO/vehicle and KO/A muciniphila mice after 2 hours of fat gavage. Triglyceride contents were comparable between these 2 groups ( Figure 4C ), suggesting that the reduced plasma chylomicrons in the A muciniphila-treated mice were unlikely the consequence of less fat absorption and chylomicron secretion of the small intestine. Next, a vitamin A excursion assay 14 was conducted to determine the clearance rate of newly secreted chylomicrons in the circulation. Fasted vehicleand A muciniphila-treated mice were given a bolus mixture of [ 3 H]-retinol and olive oil by oral gavage, and blood was sampled at various time points to determine the plasma level of 3 H counts. In the intestine, [ 3 H]-retinol is converted to fatty acid esters and incorporated into newly synthesized chylomicrons, and its only route of removal is through clearance in the liver. 14 Figure 4D , plasma level of 3 H counts were significantly higher in the KO/vehicle mice at 3.5, 7.5, and 11 hours compared with the KO/A muciniphila mice ( Figure 4D ) after the fat gavage, indicating an increased clearance of plasma chylomicrons by the liver in the KO/A muciniphila mice which may be associated with the upregulation of hepatic LDL receptors in these mice. This result is consistent with the previous reports, which showed that LDL receptors also can clear plasma triglyceriderich lipoproteins. [14] [15] [16] [17] Taken together, these data indicated that A muciniphila treatment facilitates clearance of plasma chylomicrons in CREBH-null mice via the mediation of LDL receptors.
As shown in
Increased Akkermansia muciniphila Colonization Ameliorates Hepatic Inflammation in CREBH-Null Mice
A muciniphila is a Gram-negative anaerobic gut bacterial strain that contains lipopolysaccharides in its outer cell wall. 18 Under physiological condition, the circulating level of lipopolysaccharides in the host depends on the release of lipopolysaccharides from gut bacteria and is regulated by nutritional status. 2 High-fat feeding in mice compromises the gut barrier, particularly intestinal epithelial tight junction integrity, which increases permeability of the gut and induces metabolic endotoxemia and metabolic inflammation. 2 To determine whether increased A muciniphila colonization in the gastrointestinal tract upregulates the circulating level of lipopolysaccharides, an endotoxin assay was used to measure plasma lipopolysaccharides content. As shown in Figure 5A , plasma endotoxin levels were slightly higher in CREBH-null mice compared with the WT controls, although the difference was not statistically significant ( Figure 5A) . A muciniphila inoculation did not significantly change plasma lipopolysaccharides levels in either WT or CREBH-null mice compared with their control groups ( Figure 5A ). Because increased secretion of chylomicrons has been shown to promote the absorption and transportation of purified exogenous lipopolysaccharides, 9 we thus asked whether conditions that stimulate chylomicron secretion are able to promote the absorption of endogenous lipopolysaccharides from the colonized gut bacteria, such as A muciniphila. To this end, we delivered a dose of fat (200-μL olive oil) into the A muciniphilaand the vehicle-treated control mice through oral gavage followed by poloxamer treatment to induce accumulation of chylomicrons. Blood samples were collected at 2 hours post gavage for analysis of the endotoxin content. Interestingly, the fat load-induced accumulation of chylomicrons increased plasma lipopolysaccharides levels by ≈8to 10-folds in all groups compared with the groups that did not receive fat gavage ( Figure 5 , compared 5A with 5B). However, the fat load did not particularly stimulate endogenous lipopolysaccharides release from the A muciniphila-treated mice ( Figure 5 ). This intriguing result indicates that acute fat administration did not enhance release of lipopolysaccharides from the gut bacteria that are already colonized in the gastrointestinal tract under physiological conditions. We further conducted an experiment in which a dose of A muciniphila was administrated 20 minutes post a fat load (200-μL olive oil) to determine whether administration of a fat load and A muciniphila simultaneously will increase plasma lipopolysaccharides level. As shown in Figure VI in the online-only Data Supplement, plasma lipopolysaccharides concentrations were elevated by about 4-folds in all groups compared with those mice received oil gavage only ( Figure 5B ). However, no significant difference was observed among the 4 experimental groups ( Figure VI in the online-only Data Supplement). These results suggest that chylomicron is involved in the absorption of lipopolysaccharides from dietary source, and increased colonization of A muciniphila in the gastrointestinal tract did not particularly increasing plasma lipopolysaccharides level.
Lipopolysaccharides is a strong ligand for the toll-like receptor 4 (TLR-4) and plays a critical role in the activation of the inflammatory response, including metabolic inflammation. 19 To investigate whether A muciniphila treatment stimulated TLR-4 expression in hepatocytes, we determined the protein levels of TLR-4 in the liver tissue of WT and CREBH-null mice by immunoblotting analysis at week 2 post treatment and found that expression of TLR-4 in hepatocytes was not induced by increased colonization of A muciniphila in ( Figure 5C ). In contrast, increased A muciniphila colonization reduced expression of the ER stress marker, glucose-regulated protein 94 and inhibited the activation of inflammatory transcription factors Jun-amino-terminal kinase 1 (JNK1) and JNK2 in CREBH-null mice ( Figure 5C) . A muciniphila treatment did not significantly induce stress signaling in the hepatocytes of the WT mice ( Figure 5C ). These results suggest that increased A muciniphila colonization in the gastrointestinal tract may alleviate hepatic ER stress and the inflammatory response induced by CREBH depletion.
Discussion
In this study, we unveiled a novel mechanistic link between the beneficial gut bacteria A muciniphila and the regulation of host lipoprotein metabolism and metabolic inflammation. The novel findings include the following observations: (1) increased abundance of A muciniphila in the gastrointestinal tract protected mice from an acute fat load-induced hyperlipidemia compared with the vehicle-treated mice; (2) A muciniphila treatment significantly ameliorated chronic hypertriglyceridemia induced by genetic depletion of CREBH in mice. This action was mediated by upregulating the expression of hepatic LDL receptors to facilitate clearance of triglyceride-rich lipoprotein remnants from the circulation; and (3) A muciniphila treatment improved glucose intolerance and reduced hepatic inflammatory stress induced by CREBH depletion.
The gut microbiota affect host energy and lipid metabolism and are involved in the development of metabolic diseases. 2, 20, 21 This makes it tempting to manipulate the population of different gut bacterial strains as potential therapeutic strategies for the metabolic syndrome. Studies with germ-free and conventionally raised mice have demonstrated that germ-free mice are protected against the obesity induced by high-fat and high-carbohydrate diets. 22 Colonization of adult germ-free mice with microbiota harvested from the cecum of conventionally raised mice significantly increased body fat content and induced insulin resistance within 14 days. 23 Although these studies demonstrate the critical mutualism between the gut bacteria and the host metabolic system, investigating the role of gut microbiota in the pathogenesis of metabolic disorders based on the data drawn from the entire bacterial community, including both disease-protective and disease-promoting gut bacteria complicates the characterization of the underlying molecular mechanism(s). In this study, we introduced a single strain of a beneficial gut bacterium, A muciniphila, into the host and investigated its potential protective effect on host lipoprotein metabolism and the inflammatory response. We found that increased A muciniphila abundance protected mice from acute fat load-induced overproduction of chylomicrons. A muciniphila treatment also alleviated chronic hypertriglyceridemia induced by genetic depletion of CREBH. In contrast, administration of A muciniphila did not significantly alter plasma lipid content in the WT mice under regular chow diet conditions. This observation is physiologically important because it implicates that A muciniphila may only exert its regulatory effect when the host lipid metabolism is disturbed. We further noticed that restoration of the impaired LPL activity is not the major mechanism for the triglyceride-lowering action of A muciniphila as the defective LPL cofactors, apoC2, apoA4, and apoA5, in CREBH-null mice were not restored by A muciniphila treatment.
Endogenous lipids synthesized by the liver are secreted into the circulation via VLDL particles that contain apoB100 (and apoB48 in mice) and are cleared by the LDL receptor pathway. ApoB100 and apoE are the major ligands that mediate the interaction between VLDL remnants and LDL receptor. In the circulation, LPL hydrolyzes the triglycerides in the core of the VLDL particles, resulting in the formation of IDLs. The IDL particle is cleared rapidly by the liver through receptor endocytosis mediated by LDL receptor. In this process, apoE, a high affinity ligand for the LDL receptor, on the IDL particle is critical in mediating the interaction between the IDL and the LDL receptors. A portion of IDL particles escape uptake by the liver and are further hydrolyzed into LDL, which leads to the loss of apoE. The sole remaining protein in the LDL particle, apoB100, binds to LDL receptors with relatively low affinity, thus causing LDL particles to remain in the circulation for relatively prolonged periods. 24 The hyperlipidemia observed in the CREBH-null mice are mainly in the triglyceride-rich VLDL fraction. 25 In this study, we demonstrated that increased colonization of A muciniphila not only significantly reduced triglyceride contents in the plasma VLDL particles but also corrected the elevated triglycerides in the IDL and LDL particles. This action was mediated by the A muciniphila-induced expression of hepatic LDL receptors which, in turn, facilitated the uptake of triglyceride-rich lipoprotein remnants from the circulation and reduced plasma triglycerides. Consistent with enhanced LDL receptor signaling, a small reduction of plasms cholesterol was observed in the fast-phase liquid chromatography fractions of VLDL IDL/LDL and larger HDL particles in the A muciniphila-treated CREBH-null mice. Activation of hepatic LDL receptor signaling was further supported by the accumulation of apoB100 and apoE in the hepatocytes of the A muciniphila-treated mice. Because apoE is also a component of HDL, the elevated apoE in the A muciniphilatreated hepatocytes may also be, at least partially, associated with the increased exchange between HDL-associated cholesteryl esters and triglyceride derived from apoB-containing lipoproteins (eg, IDL) during HDL-mediated reverse cholesterol transport. Further investigation is needed for better understanding the regulatory impact of A muciniphila on cholesterol metabolism.
Chronic excessive dietary fat absorption (eg, high-fat diet) has been proposed to facilitate the absorption of highly proinflammatory lipopolysaccharides from the gut bacteria, 26, 27 which in turn affects systemic inflammation via the mediation of TLR-4 and nuclear factor-κB signaling and interferes with metabolic homeostasis. Because A muciniphila is a Gram-negative bacterium that contains lipopolysaccharides, one may speculate that increased colonization of A muciniphila would elevate lipopolysaccharides in the circulation. In this study, however, we found that increased population of A muciniphila in the gastrointestinal tract did not increase plasma lipopolysaccharides levels in both WT and CREBH-null mice. Induced chylomicron secretion by an acute fat load failed to particularly upregulate circulated lipopolysaccharides levels in the A muciniphila-treated mice. Previously, administration of a fat load had been shown to enhance absorption of purified exogenous lipopolysaccharides and elevate the circulated lipopolysaccharides level. 9 In this study, when a dose of A muciniphila was administrated with a fat load simultaneously, the circulated lipopolysaccharides was elevated significantly in all groups of the experimental mice without particularly stimulating the release of lipopolysaccharides from the colonized A muciniphila. This interesting finding may suggest that acute fat load only promotes absorption of lipopolysaccharides from dietary source and is unlikely to enhance the absorption of lipopolysaccharides from A muciniphila that has already colonized in the gut. More research is definitely warranted to delineate the association between chylomicron metabolism and lipopolysaccharides absorption from dietary source or from the colonized gut bacteria.
Hyperlipidemia is closely associated with the development of hepatic ER stress and metabolic inflammation that are associated with the onset of metabolic syndrome. [28] [29] [30] In this study, we demonstrate that improvement of hyperlipidemia by A muciniphila is accompanied by the alleviation of hepatic ER stress and inflammatory signaling in CREBH-null mice. This beneficial effect leads to the improvement of systemic insulin sensitivity. Whether A muciniphila directly regulates hepatic stress signaling or the recovery of hepatocytes from ER stress is secondary to the improvement of the lipid profile after A muciniphila treatment requires further investigation. In addition, increased colonization of A muciniphila induced population changes of Bacteroidetes and Lactobacillus. Lactobacillus has been widely accepted as a probiotic strain, which contributes to gut health and body weight control, 31 whereas reduced population of Bacteroidetes was found in the gut of obese humans and animals. 32 Therefore, it is possible that increased populations of these gut bacteria may also contribute to the phenotypes observed in the A muciniphila-treated mice.
